Everything below concerns half-life. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-09. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
== Mechanisms == The effective overall energy unit for the available body energy is referred to as the daily glycogen generation capacity, and is used to compare the mitochondrial output of affected or chronically glycogen-depleted individuals to healthy individuals. The glycogen generation capacity is entirely dependent on, and determined by, the operating levels of the mitochondria in all of the cells of the human body; however, the relation between the energy generated by the mitochondria and the glycogen capacity is very loose and is mediated by many biochemical pathways. The energy output of full healthy mitochondrial function can be predicted exactly by a complicated theoretical argument, but this argument is not straightforward, as most energy is consumed by the brain and is not easily measurable.
Ann Lawthom, lately Headteacher, Rhondda Special School, Trealaw, Rhondda. For services to Education. Hilda Blanche Le Cras. For services to Horse Driving for the Disabled and to the Royal British Legion on Guernsey. Elizabeth May Leake. For charitable services in Clenchwarton, Norfolk. William Gordon John Leckie, Managing Director, Cneff Hydro Hotel, Perthshire. For services to the Hotel Industry and to Tourism. Bryan Neville Lee. For services to the Samaritans and to the community in Doncaster. Winifred Elizabeth Lees. For political and public service. Jacqueline Margaret Leete. For services to the community in Headley, Hampshire. Donald Clement Lefever. For services to the Butler Trust. Shiu-Wing Leung, Executive Officer, Ministry of Defence. Joan Lewin. For services to the Historical Association. Ann Lewis, Teacher in Charge, Widden Family Centre, Gloucester. For services to Pre-School Education. Peter Reginald Lewis, Sub-Officer (Retained), North Wales Fire Service. For services to the Fire Service. Maurice George Lihou. For services to Young Handicapped People on Guernsey. Sandra Elizabeth Linnett, lately Sales and Computer Clerk, Kopex International Ltd. For services to Industry. Rose Helena Lloyd. For services to St. David's Church, Hundleton. Adrian Neville Barrett Loach, Assistant Group Scout Leader, Bristol. For services to Scouting. Rebecca McCausland Lockhead. For public service Jean Elizabeth Lockwood. For services to the community in Amersham, Buckinghamshire. The Reverend Roy Frederick Lodge, Chaplain, Her Majesty's Prison Brockhill.
Elevated SIRs (which is risk of getting cancer) were found for subgroups in the USA cohort defined by age <35 years or childhood onset GH deficiency." The FDA issued a Safety Communication in August 2011, stating that the evidence regarding recombinant human growth hormone and increased risk of death is inconclusive after reviewing sources including a French study which compared persons with certain kinds of short stature (idiopathic growth hormone deficiency and idiopathic or gestational short stature) treated with recombinant human growth hormone during childhood and who were followed over a long period of time, with individuals in the general population of France.
To emphasise that there was now only one Indian Army, and that all units were to be trained and deployed without regard for their regional origins, the regiments were renumbered into single sequences of cavalry, artillery, infantry of the line, and Gurkha Rifles. Regimental designations were altered to remove all references to the former Presidency Armies. Where appropriate subsidiary titles recalling other identifying details were adopted. Thus the 2nd Bengal Lancers became the 2nd Lancers (Gardner's Horse). The new order began with the Bengal regiments, followed by the Punjab Frontier Force, then the regiments of Madras, the Hyderabad Contingent, and Bombay. Wherever possible a significant digit was retained in the new number. Thus the 1st Sikh Infantry became the 51st Sikhs, the 1st Madras Pioneers became the 61st Pioneers, and the 1st Bombay Grenadiers became the 101st Grenadiers. The Gurkha Regiments had developed into their own Line of rifle regiments since 1861. They were five of these until they were joined by the former 42nd, 43rd, & 44th Gurkha Regiments of the Bengal Army, who became the 6th, 7th, & 8th Gurkha Rifles. The numbers 42, 43, & 44 were allocated respectively to the Deoli and Erinpura Irregular Forces and the Mhairwara Battalion from Rajputana.
Sources: en.wikipedia.org
I abolished feudalism and restored equality to all religion and before the law. I fought the decrepit monarchies of the Old Regime because the alternative was the destruction of all this. I purified the Revolution."
Furthermore, the nitrogen atom may be replaced by a phosphorus, arsenic, or antimony atom (the heavier nonmetallic pnictogens), creating a phosphonium (PH+4) or arsonium (AsH+4) cation that can itself be substituted similarly; while stibonium (SbH+4) itself is not known, some of its organic derivatives are characterised.
The product must be thujone-free as per TTB guidelines, The word "absinthe" can neither be the brand name nor stand alone on the label, and The packaging cannot "project images of hallucinogenic, psychotropic, or mind-altering effects". Absinthe imported in violation of these regulations is subject to seizure at the discretion of U.S. Customs and Border Protection.
The spread of ironworking in Central and Western Europe is associated with Celtic expansion. According to Pliny the Elder, iron use was common in the Roman era. In the lands of what is now considered China, iron appears approximately 700–500 BC. Iron smelting may have been introduced into China through Central Asia. The earliest evidence of the use of a blast furnace in China dates to the 1st century AD, and cupola furnaces were used as early as the Warring States period (403–221 BC). Usage of the blast and cupola furnace remained widespread during the Tang and Song dynasties. During the Industrial Revolution in Britain, Henry Cort began refining iron from pig iron to wrought iron (or bar iron) using innovative production systems. In 1783 he patented the puddling process for refining iron ore. It was later improved by others, including Joseph Hall.
Just like phagocytes, pathogens may evade or infect neutrophils. Some bacterial pathogens evolved various mechanisms such as virulence molecules to avoid being killed by neutrophils. These molecules collectively may alter or disrupt neutrophil recruitment, apoptosis or bactericidal activity. Neutrophils can also serve as host cell for various parasites that infect them avoiding phagocytosis, including:
Sources: en.wikipedia.org
The Israeli Ground Forces (Hebrew: זְרוֹעַ הַיַּבָּשָׁה, romanized: z'róa hibshá, lit. 'The Land Arm') are the army of the Israel Defense Forces (IDF). The current commander of the ground forces is Major General Nadav Lotan. An order from Defense Minister David Ben-Gurion on 26 May 1948 officially set up the Israel Defense Forces as a conscript army formed out of the paramilitary group Haganah, incorporating the militant groups Irgun and Lehi. The Ground Forces have served in all the country's major military operations—including the 1948 Arab–Israeli War, 1956 Suez Crisis, 1967 Six-Day War, 1973 Yom Kippur War, 1976 Operation Entebbe, 1982 Lebanon War, 1987–1993 First Intifada, 2000–2005 Second Intifada, 2006 Lebanon War, and the Gaza War (2008–09). While originally the IDF operated on three fronts—against Lebanon and Syria in the north, Jordan and Iraq in the east, and Egypt in the south—after the 1979 Egyptian–Israeli Peace Treaty, it has concentrated in southern Lebanon and the Palestinian territories, including the First and the Second Intifada. The Ground Forces uses several technologies developed in Israel such as the Merkava main battle tank, Achzarit armoured personnel carrier, the Iron Dome missile defense system, Trophy active protection system for vehicles, and the Galil and Tavor assault rifles. The Uzi submachine gun was invented in Israel and used by the Ground Forces until December 2003, ending a service that began in 1954.
Vascular endothelial growth factor (VEGF) is one of the main inducers of endothelial cell proliferation and permeability of blood vessels. Two RTKs bind to VEGF at the cell surface, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). The VEGF receptors have an extracellular portion consisting of seven Ig-like domains so, like FGFRs, belong to the immunoglobulin superfamily. They also possess a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF. The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). A third receptor has been discovered (VEGFR-3); however, VEGF-A is not a ligand for this receptor. VEGFR-3 mediates lymphangiogenesis in response to VEGF-C and VEGF-D.
=== Pharmacokinetics === Absorption: Bioavailability (subcutaneous injection) ~ 100% Distribution: Volume of distribution (anti-Factor Xa activity) = 4.3 liters Metabolism: Enoxaparin is metabolized in the liver into low molecular weight species by either or both desulfation and depolymerization. Elimination: A single dose of a subcutaneous injection of enoxaparin has an elimination half-life of 4.5 hours. Approximately 10–40% of the active and inactive fragments from a single dose are excreted by the kidneys. Dose adjustments based on kidney function are necessary in persons with reduced kidney function.
While agreeing with the editorial's conclusion, a reply noted that its finding in the negative was guaranteed, given that "global dose estimates or results of mathematical modelling are too inaccurate to be used as dose values for an individual veteran", and that, as of April 2001, no practical method of measuring the expected small doses that each individual veteran would receive had been suggested. The author of the reply, a radiation scientist, went on to suggest a method that had been used several times before, including after the 1986 Chernobyl accident. Despite the widespread use of DU in the Iraq War, at least a year after the conflict began, testing of UK troops was still only in the discussion phase. The Royal Society Working Group on the Health Hazards of Depleted Uranium Munitions (RSDUWG) concluded in 2002 that there were "very low" health risks associated with the use of depleted uranium, though it also ventured that, "[i]n extreme conditions and under worst-case assumptions" lung and kidney damage could occur, and that in "worst-case scenarios high local levels of uranium could occur in food or water that could have adverse effects on the kidney". In 2003, the Royal Society issued another urgent call to investigate the actual health and environmental impact of depleted uranium. The same year, a cohort study of Gulf War veterans found no elevated risks of cancer generally, nor of any specific cancers in particular, though recommended follow up studies.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.